Capital Fund Management S.A. Acquires Shares of 23,386 Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Capital Fund Management S.A. bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 23,386 shares of the biopharmaceutical company's stock, valued at approximately $1,118,000.

Several other hedge funds also recently bought and sold shares of HALO. Norges Bank bought a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at approximately $60,054,000. Arrowstreet Capital Limited Partnership grew its position in Halozyme Therapeutics by 141.3% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company's stock worth $47,470,000 after acquiring an additional 581,475 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Halozyme Therapeutics during the 4th quarter worth $21,838,000. Vanguard Group Inc. raised its holdings in shares of Halozyme Therapeutics by 3.0% during the 4th quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company's stock valued at $634,999,000 after purchasing an additional 386,618 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its stake in shares of Halozyme Therapeutics by 698.8% in the 4th quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company's stock valued at $13,756,000 after purchasing an additional 251,711 shares during the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have weighed in on HALO shares. HC Wainwright reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Wells Fargo & Company reduced their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Piper Sandler upped their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research note on Friday, January 10th. Finally, Benchmark reissued a "buy" rating and issued a $75.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, Halozyme Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $62.78.

Halozyme Therapeutics Trading Down 0.1 %

NASDAQ HALO traded down $0.03 during trading hours on Friday, hitting $58.79. The company's stock had a trading volume of 1,518,839 shares, compared to its average volume of 1,425,031. Halozyme Therapeutics, Inc. has a twelve month low of $37.97 and a twelve month high of $66.00. The firm has a market capitalization of $7.26 billion, a P/E ratio of 17.14, a PEG ratio of 0.42 and a beta of 1.32. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The stock has a fifty day moving average of $60.45 and a 200 day moving average of $55.02.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The company had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, SVP Michael J. Labarre sold 1,697 shares of the firm's stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the transaction, the senior vice president now owns 173,756 shares in the company, valued at $10,126,499.68. This trade represents a 0.97 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey William Henderson sold 503 shares of the stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $64.05, for a total value of $32,217.15. Following the transaction, the director now directly owns 33,108 shares of the company's stock, valued at $2,120,567.40. This trade represents a 1.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 22,200 shares of company stock valued at $1,286,568. 2.40% of the stock is owned by corporate insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.